Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
2.
Front Immunol ; 15: 1345473, 2024.
Article in English | MEDLINE | ID: mdl-38343535

ABSTRACT

AMG 256 is a bi-specific, heteroimmunoglobulin molecule with an anti-PD-1 antibody domain and a single IL-21 mutein domain on the C-terminus. Nonclinical studies in cynomolgus monkeys revealed that AMG 256 administration led to the development of immunogenicity-mediated responses and indicated that the IL-21 mutein domain of AMG 256 could enhance the anti-drug antibody response directed toward the monoclonal antibody domain. Anti-AMG 256 IgE were also observed in cynomolgus monkeys. A first-in-human (FIH) study in patients with advanced solid tumors was designed with these risks in mind. AMG 256 elicited ADA in 28 of 33 subjects (84.8%). However, ADA responses were only robust and exposure-impacting at the 2 lowest doses. At mid to high doses, ADA responses remained low magnitude and all subjects maintained exposure, despite most subjects developing ADA. Limited drug-specific IgE were also observed during the FIH study. ADA responses were not associated with any type of adverse event. The AMG 256 program represents a unique case where nonclinical studies informed on the risk of immunogenicity in humans, due to the IL-21-driven nature of the response.


Subject(s)
Antibodies, Monoclonal , Interleukins , Programmed Cell Death 1 Receptor , Animals , Humans , Macaca fascicularis , Immunoglobulin E
3.
Bioanalysis ; 9(23): 1849-1858, 2017 Dec.
Article in English | MEDLINE | ID: mdl-29020795

ABSTRACT

BACKGROUND: Titer methods are commonly used to characterize the magnitude of an antidrug antibody response. Assay S/N is an appealing alternative, but the circumstances under which use of signal-to-noise (S/N) is appropriate have not been well defined. RESULTS: We validated both titer and S/N-based methods for several therapeutics. S/N correlated strongly with titer both in aggregate and when examined on a per subject basis. Analysis of impact of antibody magnitude on pharmacokinetics yielded the same result using either method. Each assay demonstrated excellent precision, good linearity, and adequate drug tolerance. CONCLUSION: Under these circumstances, assay S/N is a valid alternative to titer for assessment of the magnitude of an antidrug antibody response.


Subject(s)
Antibodies, Anti-Idiotypic/analysis , Antibodies, Monoclonal/immunology , Antibodies, Anti-Idiotypic/immunology , Antibodies, Monoclonal/blood , Antigen-Antibody Reactions , Humans , Immunoassay , Luminescent Measurements , Signal-To-Noise Ratio
4.
Bioanalysis ; 5(9): 1041-55, 2013 May.
Article in English | MEDLINE | ID: mdl-23641695

ABSTRACT

BACKGROUND: Immunogenicity testing is an important component of clinical development for large-molecule biotherapeutics. New complex types of large molecules, such as antibody-drug conjugates (ADCs), require careful evaluation of the testing strategy and bioanalytical assays used to monitor the development of antitherapeutic antibodies. RESULTS: An electrochemiluminescence-based immunoassay for the detection and epitope characterization of anti-ADC antibodies was validated. Using this assay format, antibodies directed against the monoclonal antibody and linker-drug components of the ADC were successfully detected in a multiple-dose rat toxicity study. CONCLUSION: Immunogenicity assays incorporating epitope determination may provide additional information about the characteristics of induced antitherapeutic antibodies, including the magnitude and timing of the various types of antibody responses.


Subject(s)
Antibodies, Monoclonal/blood , Antibodies, Monoclonal/immunology , Immunoconjugates/blood , Immunoconjugates/immunology , Immunogenetic Phenomena/immunology , Pharmaceutical Preparations/blood , Animals , Antibodies, Monoclonal/therapeutic use , Antigen-Antibody Reactions , Humans , Immunoconjugates/therapeutic use
5.
AAPS J ; 15(1): 30-40, 2013 Jan.
Article in English | MEDLINE | ID: mdl-23054969

ABSTRACT

The availability of highly sensitive immunoassays enables the detection of antidrug antibody (ADA) responses of various concentrations and affinities. The analysis of the impact of antibody status on drug pharmacokinetics (PK) is confounded by the presence of low-affinity or low-concentration antibody responses within the dataset. In a phase 2 clinical trial, a large proportion of subjects (45%) developed ADA following weekly dosing with AMG 317, a fully human monoclonal antibody therapeutic. The antibody responses displayed a wide range of relative concentrations (30 ng/mL to >13 µg/mL) and peaked at various times during the study. To evaluate the impact of immunogenicity on PK, AMG 317 concentration data were analyzed following stratification by dose group, time point, antibody status (positive or negative), and antibody level (relative concentration). With dose group as a stratifying variable, a moderate reduction in AMG 317 levels (<50%) was observed in antibody-positive subjects when compared to antibody-negative subjects, but the difference was not statistically significant in all dose groups. The most significant reduction in AMG 317 levels was revealed when antibody data was stratified by both time point and antibody level. In general, high ADA concentrations (>500 ng/mL) and later time points (week 12) were associated with significantly (up to 97%) lower trough AMG 317 concentrations. The use of quasi-quantitative antibody data and appropriate statistical methods was critical for the most comprehensive evaluation of the impact of immunogenicity on PK.


Subject(s)
Antibodies, Monoclonal/immunology , Antibodies/blood , Antibodies, Monoclonal/blood , Antibodies, Monoclonal/pharmacokinetics , Antibodies, Monoclonal, Humanized , Humans , Patient Satisfaction
6.
Pharm Res ; 28(10): 2530-42, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21604075

ABSTRACT

PURPOSE: For AMG 317, a fully human monoclonal antibody to interleukin receptor IL-4Rα, we developed a population pharmacokinetic (PK) model by fitting data from four early phase clinical trials of intravenous and subcutaneous (SC) routes simultaneously, investigated important PK covariates, and explored the relationship between exposure and IgE response. METHODS: Data for 294 subjects and 2183 AMG 317 plasma concentrations from three Phase 1 and 1 Phase 2 studies were analyzed by nonlinear mixed effects modeling using first-order conditional estimation with interaction. The relationship of IgE response with post hoc estimates of exposure generated from the final PK model was explored based on data from asthmatic patients. RESULTS: The best structural model was a two-compartment quasi-steady-state target-mediated drug disposition model with linear and non-linear clearances. For a typical 80-kg, 40-year subject, linear clearance was 35.0 mL/hr, central and peripheral volumes of distribution were 1.78 and 5.03 L, respectively, and SC bioavailability was 24.3%. Body weight was an important covariate on linear clearance and central volume; age influenced absorption rate. A significant treatment effect was observable between the cumulative AUC and IgE response measured. CONCLUSION: The population PK model adequately described AMG 317 PK from IV and SC routes over a 60-fold range of doses with two dosing strengths across multiple studies covering healthy volunteers and patients with mild to severe asthma. IgE response across a range of doses and over the sampling time points was found to be related to cumulative AMG 317 exposure.


Subject(s)
Antibodies, Monoclonal/pharmacology , Antibodies, Monoclonal/pharmacokinetics , Immunoglobulin E/metabolism , Interleukin-4 Receptor alpha Subunit/immunology , Adult , Antibodies, Monoclonal/blood , Antibodies, Monoclonal, Humanized , Area Under Curve , Asthma/drug therapy , Asthma/metabolism , Biological Availability , Body Weight , Dose-Response Relationship, Drug , Female , Humans , Infusions, Intravenous , Infusions, Subcutaneous , Interleukin-4 Receptor alpha Subunit/antagonists & inhibitors , Linear Models , Male , Models, Biological , Nonlinear Dynamics
7.
J Biol Chem ; 280(28): 26094-8, 2005 Jul 15.
Article in English | MEDLINE | ID: mdl-15908425

ABSTRACT

Protein L-isoaspartyl methyltransferase (PIMT) has been implicated in the repair or metabolism of proteins containing atypical L-isoaspartyl peptide bonds. The repair hypothesis is supported by previous studies demonstrating in vitro repair of isoaspartyl peptides via formation of a succinimide intermediate. Utilization of this mechanism in vivo predicts that PIMT modification sites should exhibit significant racemization as a side reaction to the main repair pathway. We therefore studied the D/L ratio of aspartic acid at specific sites in histone H2B, a known target of PIMT in vivo. Using H2B from canine brain, we found that Asp25 (the major PIMT target site in H2B) was significantly racemized, exhibiting d/l ratios as high as 0.12, whereas Asp51, a comparison site, exhibited negligible racemization (D/L < or = 0.01). Racemization of Asp25 was independent of animal age over the range of 2-15 years. Using H2B from 2-3-week mouse brain, we found a similar D/L ratio (0.14) at Asp25 in wild type mice, but substantially less racemization (D/L = 0.035) at Asp25 in PIMT-deficient mice. These findings suggest that PIMT functions in the repair, rather than the metabolic turnover, of isoaspartyl proteins in vivo. Because PIMT has numerous substrates in cells, these findings also suggest that D-aspartate may be more common in cellular proteins than hitherto imagined and that its occurrence, in some proteins at least, is independent of animal age.


Subject(s)
Aspartic Acid/chemistry , Histones/chemistry , Histones/metabolism , Protein D-Aspartate-L-Isoaspartate Methyltransferase/physiology , Amino Acid Sequence , Animals , Brain/metabolism , Catalysis , Chromatin/chemistry , Chromatography, High Pressure Liquid , Dogs , Models, Chemical , Molecular Sequence Data , Peptides/chemistry , Protein D-Aspartate-L-Isoaspartate Methyltransferase/metabolism , Sequence Homology, Amino Acid , Stereoisomerism , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...